Hospital
The Nemours Foundation
The Nemours Foundation was paid $104.95M by Medicaid between Jan 2018 and Dec 2024, across 303 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoTHE NEMOURS FOUNDATION
ORLANDO, FL 32827
ORLANDO, FL 32827
33aNPI1245520386assigned 04/11/2011
33bProvider typeChildren' s Chronic Disease Hospital
28Total paid$104.95M
24GClaims643,640
24DCodes billed303
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official MCKENDREE, RODNEY controls 16+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 5,250 | $514K | |
| 2019 | 124,380 | $19.74M | |
| 2020 | 100,139 | $17.81M | |
| 2021 | 156,942 | $24.60M | |
| 2022 | 121,911 | $14.22M | |
| 2023 | 86,722 | $16.70M | |
| 2024incomplete | 48,296 | $11.37M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 58,509 | 55,402 | $16.97M |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 13% | 18,398 | 12,674 | $14.07M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.9% | 33,777 | 32,389 | $9.31M |
| A9150 | Non-prescription drugs | 6.0% | 10,923 | 8,114 | $6.35M |
| J3490 | Unclassified drugs | 5.0% | 52,426 | 24,411 | $5.28M |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 3.4% | 14,375 | 4,372 | $3.52M |
| G0378 | Hospital observation service, per hour | 2.9% | 13,253 | 5,582 | $3.09M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 2.7% | 2,758 | 2,566 | $2.88M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 2.4% | 9,362 | 8,811 | $2.50M |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.1% | 1,431 | 1,304 | $2.22M |
| J2704 | Injection, propofol, 10 mg | 2.0% | 17,641 | 14,524 | $2.05M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 10,075 | 2,755 | $2.04M |
291 more codes
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 1.6% | 19,475 | $1.70M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 3,997 | $1.54M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.5% | 2,710 | $1.53M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.4% | 11,351 | $1.48M |
| 54300 | 1.2% | 907 | $1.27M | |
| 42830 | 1.1% | 566 | $1.17M | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 1.1% | 7,183 | $1.14M |
| 93303 | Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study | <1% | 1,532 | $1.03M |
| 76770 | <1% | 4,062 | $906K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 3,063 | $863K |
| 99285 | Emergency room visit (most serious) | <1% | 3,684 | $829K |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 3,578 | $738K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 1,575 | $687K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,266 | $659K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 2,080 | $647K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 2,005 | $616K |
| 80053 | Comprehensive metabolic panel | <1% | 10,034 | $598K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,367 | $585K |
| 54161 | <1% | 897 | $582K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,331 | $534K |
| 97161 | <1% | 1,768 | $505K | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 3,695 | $484K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,414 | $483K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,179 | $463K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,460 | $452K |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 2,239 | $372K |
| 93304 | <1% | 643 | $356K | |
| 74018 | <1% | 6,135 | $354K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,277 | $354K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 7,086 | $347K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,004 | $322K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 550 | $314K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,330 | $311K |
| 96367 | <1% | 455 | $277K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,361 | $271K |
| J3535 | Drug administered through a metered dose inhaler | <1% | 1,707 | $261K |
| 73090 | <1% | 1,832 | $255K | |
| 01922 | <1% | 1,733 | $250K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,467 | $247K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,150 | $238K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 3,286 | $223K |
| 72082 | <1% | 2,610 | $222K | |
| 86900 | <1% | 2,130 | $210K | |
| 92523 | <1% | 820 | $198K | |
| 72170 | <1% | 2,457 | $198K | |
| 74230 | <1% | 717 | $197K | |
| 76536 | <1% | 1,128 | $183K | |
| 87631 | <1% | 2,153 | $171K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 236 | $165K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 118 | $161K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,936 | $156K |
| 70360 | <1% | 1,731 | $152K | |
| 73610 | <1% | 1,292 | $151K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 716 | $148K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 447 | $145K |
| 97166 | <1% | 539 | $144K | |
| J3262 | Injection, tocilizumab, 1 mg | <1% | 274 | $143K |
| 77072 | <1% | 1,497 | $134K | |
| 87275 | <1% | 1,868 | $127K | |
| 76870 | <1% | 780 | $126K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | <1% | 283 | $124K |
| 73630 | <1% | 1,402 | $119K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 18,233 | $115K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,750 | $113K |
| 67311 | <1% | 28 | $113K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,447 | $109K |
| 74240 | <1% | 747 | $107K | |
| 93975 | <1% | 539 | $107K | |
| 54640 | <1% | 68 | $107K | |
| 36430 | <1% | 337 | $107K | |
| 00126 | <1% | 1,486 | $104K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 670 | $100K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 447 | $99K |
| 72081 | <1% | 1,162 | $95K | |
| 29888 | <1% | 13 | $94K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,500 | $90K |
| 00170 | Anesthesia for intraoral procedures, including biopsy | <1% | 3,751 | $88K |
| 44970 | <1% | 12 | $88K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,635 | $88K |
| 73080 | <1% | 629 | $88K | |
| 96415 | <1% | 595 | $85K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 743 | $85K |
| 82657 | <1% | 569 | $80K | |
| 72141 | <1% | 542 | $78K | |
| 74019 | <1% | 2,929 | $78K | |
| 73590 | <1% | 919 | $76K | |
| 82962 | <1% | 3,764 | $75K | |
| 12011 | <1% | 310 | $75K | |
| 81025 | <1% | 3,349 | $75K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 4,372 | $74K |
| 92526 | <1% | 943 | $74K | |
| 73140 | <1% | 633 | $74K | |
| 77073 | <1% | 992 | $72K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 683 | $72K |
| 97162 | <1% | 335 | $71K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,045 | $66K |
| 71045 | Radiologic examination, chest; single view | <1% | 3,162 | $66K |
| 73562 | <1% | 623 | $66K | |
| 87486 | <1% | 1,056 | $65K | |
| 93325 | <1% | 3,238 | $64K | |
| 95716 | <1% | 87 | $63K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,390 | $62K |
| 92630 | <1% | 467 | $62K | |
| 86140 | <1% | 2,978 | $61K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,375 | $61K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,830 | $58K |
| 73130 | <1% | 522 | $57K | |
| 76000 | <1% | 1,396 | $54K | |
| 87077 | <1% | 1,155 | $54K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 6,709 | $47K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 775 | $40K |
| 96409 | <1% | 178 | $38K | |
| L8699 | Prosthetic implant, not otherwise specified | <1% | 786 | $36K |
| 73552 | <1% | 508 | $36K | |
| 69610 | <1% | 15 | $34K | |
| 88300 | <1% | 1,995 | $33K | |
| 81003 | <1% | 3,136 | $33K | |
| 00920 | <1% | 1,691 | $29K | |
| 76882 | <1% | 344 | $29K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 231 | $28K |
| 74455 | <1% | 68 | $27K | |
| 81001 | <1% | 5,379 | $26K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 130 | $26K |
| 73560 | <1% | 351 | $25K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,363 | $23K |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 510 | $23K |
| 93308 | <1% | 41 | $22K | |
| 89050 | <1% | 251 | $22K | |
| 94618 | <1% | 61 | $21K | |
| 97032 | <1% | 79 | $21K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 357 | $20K |
| G0379 | Direct admission of patient for hospital observation care | <1% | 1,465 | $20K |
| 74241 | <1% | 160 | $19K | |
| 87420 | <1% | 210 | $18K | |
| 97116 | <1% | 166 | $17K | |
| 72197 | <1% | 26 | $16K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,988 | $15K |
| A9698 | Non-radioactive contrast imaging material, not otherwise classified, per study | <1% | 93 | $14K |
| 95700 | <1% | 71 | $14K | |
| J7510 | Prednisolone oral, per 5 mg | <1% | 61 | $14K |
| 31622 | <1% | 13 | $13K | |
| 76885 | <1% | 70 | $13K | |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | <1% | 279 | $13K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 120 | $12K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,058 | $12K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 184 | $11K |
| 73521 | <1% | 91 | $11K | |
| 36591 | <1% | 1,608 | $11K | |
| 94010 | <1% | 251 | $11K | |
| 87070 | <1% | 584 | $11K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 82 | $11K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 608 | $10K |
| 93976 | <1% | 922 | $10K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 5,740 | $9K |
| 80305 | <1% | 325 | $9K | |
| 00300 | <1% | 403 | $9K | |
| 70480 | <1% | 53 | $9K | |
| 87507 | <1% | 270 | $8K | |
| 00400 | <1% | 97 | $8K | |
| 97165 | <1% | 61 | $8K | |
| 93017 | <1% | 44 | $8K | |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 196 | $8K |
| 93000 | <1% | 308 | $8K | |
| 92610 | <1% | 25 | $8K | |
| 72146 | <1% | 435 | $8K | |
| 85610 | <1% | 648 | $7K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,417 | $6K |
| 96450 | <1% | 18 | $6K | |
| 92611 | <1% | 761 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 794 | $6K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 14 | $6K |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 23 | $5K |
| 88304 | <1% | 754 | $5K | |
| 87040 | <1% | 2,103 | $5K | |
| 00731 | <1% | 713 | $5K | |
| 51600 | <1% | 56 | $5K | |
| 77080 | <1% | 45 | $5K | |
| 00120 | <1% | 266 | $5K | |
| 82803 | <1% | 728 | $5K | |
| 94664 | <1% | 313 | $5K | |
| 93320 | <1% | 1,472 | $4K | |
| 86885 | <1% | 2,104 | $4K | |
| 86901 | <1% | 2,104 | $4K | |
| 92015 | Determination of refractive state | <1% | 137 | $4K |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,171 | $4K |
| 92567 | <1% | 177 | $3K | |
| 75561 | <1% | 12 | $3K | |
| 72100 | <1% | 73 | $3K | |
| 85651 | <1% | 1,704 | $3K | |
| 73070 | <1% | 29 | $3K | |
| 86850 | <1% | 1,633 | $3K | |
| 73564 | <1% | 25 | $3K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 1,192 | $3K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 2,898 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,313 | $3K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 200 | $3K |
| 87045 | <1% | 12 | $2K | |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 30 | $2K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 352 | $2K |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,704 | $2K |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | <1% | 1,615 | $2K |
| 84439 | <1% | 30 | $2K | |
| 74270 | <1% | 12 | $2K | |
| 49452 | <1% | 48 | $2K | |
| 86923 | <1% | 502 | $2K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,128 | $2K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 13 | $2K |
| 97533 | <1% | 72 | $2K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 2,738 | $2K |
| 92060 | <1% | 16 | $2K | |
| 84703 | <1% | 94 | $2K | |
| 69210 | <1% | 12 | $1K | |
| 97542 | <1% | 14 | $1K | |
| 85045 | <1% | 1,055 | $1K | |
| 87581 | <1% | 1,056 | $1K | |
| 73110 | <1% | 27 | $1K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 3,272 | $1K |
| 83690 | <1% | 1,216 | $1K | |
| 83735 | <1% | 871 | $1K | |
| 84484 | <1% | 349 | $1K | |
| 73100 | <1% | 13 | $1K | |
| 82150 | <1% | 230 | $1K | |
| 83880 | <1% | 273 | $836.42 | |
| 87430 | <1% | 16 | $828.94 | |
| 93321 | <1% | 958 | $794.75 | |
| 82728 | <1% | 376 | $764.47 | |
| 73060 | <1% | 12 | $751.42 | |
| 87276 | <1% | 1,863 | $737.68 | |
| 74183 | <1% | 12 | $642.74 | |
| 73030 | <1% | 28 | $640.50 | |
| 00124 | <1% | 12 | $518.01 | |
| J7999 | Compounded drug, not otherwise classified | <1% | 464 | $500.69 |
| 82438 | <1% | 13 | $431.36 | |
| 73000 | <1% | 17 | $417.83 | |
| 87186 | <1% | 957 | $386.12 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 13 | $345.42 |
| 92652 | <1% | 27 | $338.98 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,497 | $337.20 |
| 86308 | <1% | 14 | $214.71 | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 75 | $202.33 |
| 70250 | <1% | 12 | $164.94 | |
| 84100 | <1% | 752 | $153.50 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 648 | $127.03 |
| 88342 | <1% | 108 | $119.14 | |
| 76376 | <1% | 493 | $99.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,145 | $97.71 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,429 | $78.39 |
| 85730 | <1% | 572 | $69.94 | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 387 | $61.30 |
| 84156 | <1% | 61 | $57.56 | |
| 82570 | <1% | 85 | $57.56 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 643 | $33.08 |
| S0028 | Injection, famotidine, 20 mg | <1% | 691 | $33.08 |
| 00140 | <1% | 119 | $32.00 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 116 | $27.12 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 58 | $21.48 |
| 00840 | <1% | 91 | $21.32 | |
| 96376 | <1% | 273 | $17.09 | |
| 88108 | <1% | 31 | $10.66 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 477 | $5.88 |
| 00813 | <1% | 91 | $5.88 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 56 | $5.33 |
| 88302 | <1% | 12 | $5.33 | |
| 85384 | <1% | 31 | $5.08 | |
| 83615 | <1% | 122 | $3.22 | |
| 84550 | <1% | 55 | $3.22 | |
| 85379 | 0% | 42 | $0.00 | |
| 85660 | 0% | 62 | $0.00 | |
| 86905 | 0% | 120 | $0.00 | |
| 80329 | 0% | 16 | $0.00 | |
| J2430 | Injection, pamidronate disodium, per 30 mg | 0% | 27 | $0.00 |
| 82550 | 0% | 88 | $0.00 | |
| 83021 | 0% | 45 | $0.00 | |
| 87046 | 0% | 14 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 12 | $0.00 |
| J7612 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg | 0% | 22 | $0.00 |
| 83036 | Hemoglobin; glycosylated (A1C) | 0% | 15 | $0.00 |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 0% | 301 | $0.00 |
| 84145 | 0% | 91 | $0.00 | |
| 95873 | 0% | 31 | $0.00 | |
| J7699 | Noc drugs, inhalation solution administered through dme | 0% | 15 | $0.00 |
| 01470 | 0% | 12 | $0.00 | |
| 29125 | 0% | 14 | $0.00 | |
| 92585 | 0% | 26 | $0.00 | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 18 | $0.00 |
| J7676 | Pentamidine isethionate, inhalation solution, compounded product, administered through dme, unit dose form, per 300 mg | 0% | 26 | $0.00 |
| J9260 | Injection, methotrexate sodium, 50 mg | 0% | 17 | $0.00 |
| S0030 | Injection, metronidazole, 500 mg | 0% | 18 | $0.00 |
| 93356 | 0% | 28 | $0.00 | |
| A4649 | Surgical supply; miscellaneous | 0% | 22 | $0.00 |
| 87641 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCKENDREE, RODNEY (VP, FINANCE)
Parent organizationTHE NEMOURS FOUNDATION
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.